Verastem, Inc. Cofounders to Present at Massachusetts Institute of Technology (MIT) Breakfast on Breakthrough Discoveries in Cancer Stem Cells

Published: Feb 27, 2013

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that Robert Weinberg, Ph.D., Verastem scientific cofounder and chair of the Scientific Advisory Board, and Christoph Westphal, M.D., Ph.D., Verastem cofounder, Chairman and CEO, will present at the MIT Technology Breakfast on February 28, 2013, at 8am ET.

Back to news